TCR2 Therapeutics (TCRR) PT Lowered to $56 at BMO Capital
Tweet Send to a Friend
BMO Capital analyst Do Kim lowered the price target on TCR2 Therapeutics (NASDAQ: TCRR) to $56.00 (from $65.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
